🇺🇸 FDA

Intelligence · Clinical Pipeline

Oncology · Phase II

Oncology programs at Phase II — ClinicalTrials.gov pipeline intelligence.

Programs
2,640

Quick answer

Oncology Phase II programs: NovaPharmaNews indexes 2,640 matching clinical development programs from ClinicalTrials.gov with sponsor, modality, and NCT cross-links.

Top sponsors

Page 10 of 55

  1. Bevacizumab

    The First People's Hospital of Lianyungang

    Ovarian Cancer

    phase 2 small molecule active

    1 trial

  2. Bevacizumab

    ONCOLYTICS BIOTECH INC

    Ras-mutated Metastatic Colorectal Cancer

    phase 2 small molecule active

    1 trial

  3. Bevacizumab combined with Oxaliplatin and TAS-102

    The First People's Hospital of Lianyungang

    Advanced Colorectal Cancer

    phase 2 small molecule active

    1 trial

  4. Bevacizumab+Toripalimab+gemcitabine, adjuvant with Bevacizumab and Toripalimab

    The First People's Hospital of Lianyungang

    Nasopharyngeal Carcinoma

    phase 2 small molecule active

    1 trial

  5. Bexarotene

    LIGAND PHARMACEUTICALS INC

    Lung Cancer

    phase 2 small molecule completed

    1 trial

  6. Bexarotene

    LIGAND PHARMACEUTICALS INC

    Sarcoma, Kaposi

    phase 2 small molecule completed

    1 trial

  7. Bexarotene (targretin)

    LIGAND PHARMACEUTICALS INC

    Carcinoma, Non-small-cell Lung

    phase 2 small molecule terminated

    1 trial

  8. Bexmarilimab

    Lacuna Pharma Pty Ltd

    Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Acute Myeloid Leukemia

    phase 2 small molecule active

    1 trial

  9. Bezuclastinib in combination with sunitinib

    Cogent Biosciences

    Gastrointestinal Stromal Tumors

    phase 2 small molecule active

    1 trial

  10. Bicalutamide

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Breast Neoplasms

    phase 2 small molecule active

    1 trial

  11. BinD19

    The First People's Hospital of Lianyungang

    Relapsed B-cell Acute Lymphoblastic Leukemia

    phase 2 mab active

    1 trial

  12. Binimetinib

    United Therapeutics Europe Ltd

    Metastatic Colorectal Carcinoma

    phase 2 small molecule completed

    1 trial

  13. Binimetinib

    United Therapeutics Europe Ltd

    Locally Advanced Pancreatic Carcinoma

    phase 2 small molecule terminated

    1 trial

  14. Bispecific antibody-based combined with CAR-T cell therapy

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    B-cell Non-Hodgkin Lymphoma

    phase 2 small molecule active

    1 trial

  15. Blinatumomab

    BEONE MEDICINES AUS PTY LTD

    B Cell Precursor Acute Lymphoblastic Leukemia

    phase 2 small molecule active

    1 trial

  16. Blinatumomab

    Takeda

    Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive

    phase 2 mab active

    1 trial

  17. Blinatumomab

    BEONE MEDICINES AUS PTY LTD

    Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia

    phase 2 small molecule active

    1 trial

  18. Blinatumomab

    Amgen

    B Precursor Acute Lymphoblastic Leukemia

    phase 2 small molecule active

    1 trial

  19. Blinatumomab

    The First People's Hospital of Lianyungang

    B-cell Acute Lymphoblastic Leukemia

    phase 2 small molecule active

    1 trial

  20. Blinatumomab SC2

    Amgen

    Relapsed/Refractory (R/R) and Minimal Residual Disease Positive (MRD+) B-Cell Precursor Acute Lymphoblastic Leukemia

    phase 2 small molecule active

    1 trial

  21. Blinatumomab plus Reduced-dose Chemotherapy

    The First People's Hospital of Lianyungang

    Precursor B-Cell Acute Lymphoblastic Leukemia

    phase 2 small molecule active

    1 trial

  22. Blood test

    Yang Xiaotian

    Cancer of Colon

    phase 2 other completed

    1 trial

  23. Bortezomib

    Takeda

    Non-Germinal B-Cell-like (GCB) Diffuse Large B-cell Lymphoma (DLBCL)

    phase 2 small molecule completed

    1 trial

  24. Bortezomib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Plasma Cell Leukemia

    phase 2 small molecule active

    1 trial

  25. Bosutinib, Bosutinib, Bosulif 100 mg film-coated tablets, Bosulif 500 mg film-coated tablets, Bosulif 100 mg film-coated tablets, Bosulif 100 mg film-coated tablets, Bosulif 500 mg film-coated tablets

    Disc Medicine

    Chronic Myeloid Leukemia

    phase 2 small molecule active

    1 trial

  26. Braftovi 75 mg hard capsules, Erbitux 5 mg/mL solution for infusion

    CERO THERAPEUTICS HOLDINGS, INC.

    BRAF V600E-MUTATED LOCALISED COLON OR UPPER RECTUM CANCER

    phase 2 small molecule active

    1 trial

  27. Braftovi 75 mg hard capsules, LIBTAYO 350 mg concentrate for solution for infusion., Mektovi 15 mg film-coated tablets, Fianlimab, Braftovi 50 mg hard capsules

    Disc Medicine

    Melanoma

    phase 2 small molecule active

    1 trial

  28. Braftovi 75 mg hard capsules, Mektovi 15 mg film-coated tablets

    CERO THERAPEUTICS HOLDINGS, INC.

    BRAFV600E-mutant metastatic Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  29. Brentuximab Vedotin

    Takeda

    Enteropathy Associated T-cell Lymphoma

    phase 2 small molecule completed

    1 trial

  30. Brentuximab Vedotin

    United Therapeutics Europe Ltd

    Ann Arbor Stage IB Hodgkin Lymphoma

    phase 2 small molecule active

    1 trial

  31. Brentuximab Vedotin in Combination with Tislelizumab

    Takeda

    NK/T Cell Lymphoma Nos

    phase 2 small molecule active

    1 trial

  32. Brentuximab vedotin

    Takeda

    Relapsed or Refractory Hodgkin Lymphoma

    phase 2 small molecule completed

    1 trial

  33. BrentuximabVedotin (BV)

    Takeda

    Hodgkin Lymphoma

    phase 2 small molecule active

    1 trial

  34. Brigatinib

    Takeda

    Lymphoma, Large-Cell, Anaplastic

    phase 2 small molecule completed

    1 trial

  35. Brigatinib

    Takeda

    Anaplastic Large Cell Lymphoma, ALK-Positive

    phase 2 small molecule active

    1 trial

  36. Brigatinib

    Takeda

    Anaplastic Lymphoma Kinase Positive (ALK +) Anaplastic Large Cell Lymphoma

    phase 2 small molecule terminated

    1 trial

  37. Brigatinib

    Takeda

    Carcinoma, Non-Small-Cell Lung

    phase 2 small molecule completed

    1 trial

  38. Budenofalk 3mg magensaftresistente Hartkapseln, ALIMTA 100 mg powder for concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion., CISPLATINE ACCORD 1 mg/ml, solution à diluer pour perfusion, Carboplatin-GRY® 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Cisplatin NeoCorp 1 mg/ml - Konzentrat zur Herstellung einer Infusionslösung, Pemetrexed Accord 25 mg/ml concentrate for solution for infusion, Cisplatin Teva® 1 mg/ml Konzentrat zur Herstellung einer Infu

    Hoffmann-La Roche

    Untreated Advanced or Metastatic Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  39. Budenofalk 4 mg Zäpfchen, placebo to test

    Dr. Falk Pharma GmbH

    Acute radiation proctitis symptoms in male patients aged 18 years or older with prostate carcinoma

    phase 2 small molecule active

    1 trial

  40. Budigalimab, Sorafenib STADA 200 mg Filmtabletten, Livmoniplimab, Kisplyx 4 mg hard capsules

    AbbVie Deutschland GmbH & Co. KG

    Hepatocellular Carcinoma

    phase 2 small molecule active

    1 trial

  41. Busulfan

    Children's Hospital of Fudan University

    Juvenile Myelomonocytic Leukemia

    phase 2 small molecule completed

    1 trial

  42. C225 (cetuximab)

    The First People's Hospital of Lianyungang

    Nasopharyngeal Carcinoma

    phase 2 small molecule completed

    1 trial

  43. CABOMETYX 20 mg film-coated tablets, CABOMETYX 40 mg film-coated tablets, IMFINZI 50 mg/mL concentrate for solution for infusion., IMFINZI 50 mg/mL concentrate for solution for infusion., CABOMETYX 20 mg film-coated tablets, IMFINZI 50 mg/mL concentrate for solution for infusion., CABOMETYX 20 mg film-coated tablets, CABOMETYX 40 mg film-coated tablets, CABOMETYX 40 mg film-coated tablets, IMFINZI 50 mg/mL concentrate for solution for infusion., CABOMETYX 20 mg film-coated tablets, CABOMETYX 40 mg film-coat

    Fondazione Telethon ETS

    bladder carcinoma of urothelial and non-urothelial histology

    phase 2 small molecule active

    1 trial

  44. CABOMETYX 40 mg film-coated tablets, CABOMETYX 20 mg film-coated tablets, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    The George Institute

    Advanced /metastatic sarcomas: undifferentiated pleomorphic sarcoma, osteosarcoma and Ewing sarcoma.

    phase 2 small molecule active

    1 trial

  45. CABOMETYX 40 mg film-coated tablets, CABOMETYX 60 mg film-coated tablets, CABOMETYX 20 mg film-coated tablets

    Fondazione Telethon ETS

    Non small-cell lung cancer

    phase 2 small molecule active

    1 trial

  46. CABOMETYX 60 mg film-coated tablets, CABOMETYX 40 mg film-coated tablets, CABOMETYX 20 mg film-coated tablets

    Ipsen

    Unresectable, Locally Advanced or Metastatic Renal Cell Carcinoma with a Clear-Cell Component Who Progressed After 1st Line Treatment with Checkpoint Inhibitors

    phase 2 small molecule active

    1 trial

  47. CABOZANTINIB

    Fondazione Telethon ETS

    Patients with metastatic clear cell renal cell carcinoma pretreated with immunocheckpoints inhibitors.

    phase 2 small molecule active

    1 trial

  48. CABOZANTINIB, CABOZANTINIB, LANREOTIDE, CABOZANTINIB

    Fondazione Telethon ETS

    gastroenteropancreatic (GEP) and thoracic neuroendocrine tumor (NET)

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many oncology Phase II programs exist?

2,640 programs match both the therapeutic area and stage filters in our published index.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.